ACH 15

Drug Profile

ACH 15

Alternative Names: ACH15

Latest Information Update: 26 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ache Laboratories
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation

Most Recent Events

  • 18 Oct 2016 Ache Laboratorios terminates a phase-I clinical trial for inflammation in Brazil (PO) (NCT01702675)
  • 04 Jan 2016 Phase-I clinical trials in inflammation in Brazil (PO) prior to January 2016 (Ache laboratories pipeline, January 2016)
  • 05 Oct 2012 Preclinical trials in Undefined indication in Brazil (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top